Glycation, glycoxidation and diabetes mellitus;Glycation, glycoxydation et diabète

Nephrologie et Therapeutique

Volumn 2, Issue SUPPL. 1, 2006, Pages

  Boulanger, Éric ^a,b,c   Wautier, Jean Luc ^b   Dequiedt, Philippe ^a   Schmidt, Anne Marie ^c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^c Columbia University ^*  (United States)

Author keywords

Diabetes mellitus; Glycation; Macroangiopathy; Microangopathy; Oxidation; Renal failure

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINOGUANIDINE; CARBOHYDRATE; CELL RECEPTOR; COLLAGEN; COLONY STIMULATING FACTOR 1; DNA; GALECTIN 3; HEXOSAMINE; HEXOSE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PAPAIN; PEPSIN A; POLYOL; PROTEIN KINASE C; PROTEIN P60; SUPEROXIDE; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

AGING; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL WALL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; GLOMERULOSCLEROSIS; GLUCOSE OXIDATION; GLYCATION; HUMAN; INFLAMMATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MACROPHAGE; MESANGIUM CELL; MESOTHELIUM CELL; OXIDATIVE STRESS;

EID: 31544433979     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
2. Witowski J, Bender T, Wisniewska-Elnur J, Ksiazek K, Passlick-Deetjen J, Breborowicz A, et al. Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se. Perit Dial Int 2003;23:381-90.
3. Morgan LW, Wieslander A, Davies M, Horiuchi T, Ohta Y, Beavis MJ, et al. Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration. Kidney Int 2003;64:1854-66.
4. Liu BF, Miyata S, Hirota Y, Higo S, Miyazaki H, Fukunaga M, et al. Methylglyoxal induces apoptosis through activation of p38 mitogen-activated protein kinase in rat mesangial cells. Kidney Int 2003;63:947-57.
5. Maillard L. Action des acides aminés sur les sucres; formation des melanoïdes par voie methodique. CR Acad Sci (Paris) 1912;154:66-68.
6. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984;101:527-37.
7. Boulanger E, Dequiedt P, Wautier JL. Advanced glycosylation end products (AGE): new toxins? Nephrologie 2002;23:351-59.
8. Wautier J. Advanced glycosylation end products or glycotoxins: under-evaluated components of diet? Rev Prat 2001;51(13):1397-99.
9. Thornalley PJ. The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the concept. Biochem Soc Trans 2003;31:1341-42.
10. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-42.
11. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 1998;9:2349-56.
12. Miyata T, Ueda Y, Yoshida A, Sugiyama S, Iida Y, Jadoul M, et al. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 1997;51:880-87.
13. Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy. Perit Dial Int 1989;9:41-5.
14. Boulanger E, Wautier MP, Gane P, Mariette C, Devuyst O, Wautier JL. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol Dial Transplant 2004;19:2208-16.
15. Linden T, Forsback G, Deppisch R, Henle T, Wieslander A. 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 1998;18:290-93.
16. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsilon- carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986;261:4889-94.
17. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med 1976;295:417-20.
18. Iberg N, Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J. Biol. Chem. 1986;261:13542-13545.
19. Chappey O, Dosquet C, Wautier MP, Wautier JL. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 1997;27:97-108.
20. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A 1992;89:12043-7.
21. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995;1:634-46.
22. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992;267:14987-97.
23. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 1994;91:7742-6.
24. Boulanger E, Wautier M, Wautier J, Boval B, Panis Y, Wernert N, et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002;61:148-56.
25. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55.
26. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by Advanced Glycation End-products (AGEs) links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001;280:E685-E94.
27. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997;272:16498-506.
28. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997;99:457-68.
29. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986;232:1629-32.
30. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993;143:1649-56.
31. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 1997;40:764-69.
32. Hammes HP, Alt A, Niwa T, Clausen JT, Bretzel RG, Brownlee M, et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999;42:728-36.
33. Mortier S, Faict D, Schalkwijk C, Lameire N, De Vriese A. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. Kidney Int 2004;66:1257-65.
34. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000;11:1656-66.
35. Drueke TB. Beta2-microglobulin and amyloidosis. Nephrol Dial Transplant 2000;15 Suppl 1:17-24.
36. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994;93:521-28.
37. Wautier JL, Paton RC, Wautier MP, Pintigny D, Abadie E, Passa P, et al. Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and its relation to vascular complications. N Engl J Med 1981;305:237-42.
38. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996;97:238-43.
39. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996;45 Suppl 3:S77-80.
40. Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004;95:233-38.
41. Lobo CL, Bernardes RC, Cunha Vaz JG. Alterations of the blood-retinal barrier and retinal thickness in preclinical retinopathy in subjects with type 2 diabetes. Arch Ophthalmol 2000;118:1364-69.
42. Boeri D, Maiello M, Lorenzi M. Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes 2001;50:1432-39.
43. Chibber R, Molinatti PA, Rosatto N, Lambourne B, Kohner EM. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia 1997;40:156-64.
44. Treins C, Giorgetti-Peraldi S, Murdaca J, E VO. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 2001;276:43836-41.
45. Wendt T, Tanji N, Guo J, Hudson B, Bierhaus A, Ramasamy R, et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003;14:1383-95.
46. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162:1123-37.
47. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261-68.
48. Pugliese G, Pricci F, Iacobini C, Leto G, Amadio L, Barsotti P, et al. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J 2001;15:2471-9.
49. Krishnamurti U, Rondeau E, Sraer JD, Michael AF, Tsilibary EC. Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix. J Biol Chem 1997;272:27966-70.
50. Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001;159:513-25.
51. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-360.
52. Devuyst O, van Ypersele de Strihou C. Nitric oxide, advanced glycation end products, and uremia. Kidney Int 2000;58:1814-15.
53. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996;271:C1424-37.
54. Asahi K, Ichimori K, Nakazawa H, Izuhara Y, Inagi R, Watanabe T, et al. Nitric oxide inhibits the formation of advanced glycation end products. Kidney Int 2000;58:1780-87.
55. Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res 2000;86:E50-4.
56. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87:432-38.
57. Silvestre JS, Tamarat R, Ebrahimian TG, Le Roux A, Clergue M, Emmanuel F, et al. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res 2003;93:114-23.
58. Devuyst O. New insights in the molecular mechanisms regulating peritoneal permeability. Nephrol Dial Transplant 2002;17:548-51.
59. Rossert J, Ronco P. How to slow the progression of chronic renal insufficiency. Rev Prat 2001;51:378-84.
60. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, Baliga S, et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 42:532-38.
61. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9:294-99.
62. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001;12:2098-107.
63. Tamarat R, Silvestre JS, Huijberts M, Benessiano J, Ebrahimian TG, Duriez M, et al. Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice. Proc Natl Acad Sci U S A 2003;100:8555-60.
64. Bakris G, Bank A, Kass D, Neutel J, Preston R, Oparil S. Advanced glycation end-product cross-link breakers: a novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 2004;17:23S-30S.